Business
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, expands management with the addition of Dr. Simon Wood PhD, a seasoned scientist that will help expand PetLife’s product line with new patents and drugs.\n Simon Wood PhD, FRSC(UK), CChem, CSci Dr Wood is an Adjunct Professor at the University of British Columbia, Food, Nutrition and Health Program and an Adjunct Professor at the School of Public Health, Faculty of Health Sciences, Curtin University, Australia. He has over 35 years of experience gained on three continents managing chemical companies, developing proprietary natural products and their global markets and lecturing at a medical university. He has worked on the science behind various natural products for the last 15 years from start-ups to multinational; developing data for safety, pre-clinical, human trials, regulatory status and patents. He has published over 30 peer reviewed papers and has several patents. His interests are in developing science on natural products from structural identification through preclinical studies to human trials at CRO’s and Universities around the world and then using these to attain status with regulators globally that helps facilitate sales. Other interest involves combining natural products with Pharmaceutical products. PetLife’s CEO, Dr. Salvagno, commented “The addition of Dr. Wood to our team will expand our internal knowledgebase of the industry and the potential reach of PetLife in the veterinarian pharmaceutical space. It is critical for the growth of our company to have a pipeline of new drugs. New drugs and patents are important to the success of the company and in building shareholder wealth. The goal of PetLife was never to be a single product company. Dr. Wood will assist the company in researching potential drugs for PetLife to acquire or develop that would immediately expand the company's pharmaceutical product line. One of these potential drug candidates under consideration and review is already in Phase 3 trials on the human side and would potentially have a big impact in Veterinarian medicine. The additional products we are researching and already negotiating with address the...